The human cellular kinome contains over 500 kinases, accounting for almost 2% of all our genes. It is currently impossible to gauge the phosphorylation status, or even phosphorylation potential, of ...

The Chan Zuckerberg Initiative (CZI) announced four multi-year Exploratory Cell Networks grants for researchers exploring the frontiers of genomics, cell biology, and synthetic biology by developing ...

Protein kinases are arguably the most tractable candidates for development of new therapies to treat cancer. Deep sequencing of breast cancer cell lines indicates each express 375 or so kinases, ...

When it comes to finding therapeutic cancer targets, “mutated cancer genes are just the tip of the iceberg, but functional genomics can help uncover the much larger, submerged portion of the iceberg,” ...

SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), announced today that it has entered into an exclusive license ...

Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC ...

Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.

Kinases have emerged in recent years as promising targets for therapeutic intervention, unsurprisingly, as mutations in kinase domains have been linked to an array of human disorders—most notably ...

SCHINDELLEGI, SCHWYZ, SWITZERLAND, June 30, 2025 /EINPresswire / -- AsedaSciences, a pioneer in AI-powered cellular response profiling of chemicals and associated predictive toxicity risk assessment, ...

Aptose Biosciences Inc. has bought over the worldwide rights to Hanmi Pharmaceutical Co. Ltd.’s myeloid kinome inhibitor in a deal worth up to $420 million. Seoul, South Korea-based Hanmi has granted ...